Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 3;22(11):3499-3507.
doi: 10.1021/acs.jproteome.3c00356. Epub 2023 Oct 16.

Untargeted Metabolomic Study of Lung Cancer Patients after Surgery with Curative Intent

Saida Sanchez-Espirilla  1   2 , Antonio Pereira-Vega  3 , Belén Callejón-Leblic  1 , Isabel Díaz-Olivares, Rafael Santana  4 , Carolina Gotera Rivera  4 , José Luis Gómez-Ariza  1 , José Luis López-Campos  5   6   7 , Ana Isabel Blanco-Orozco  5   6 , Luis Seijo  8 , María Rodríguez  8 , Luis Alejandro Padrón Fraysse  3 , Ángeles Herrera-Chilla  3 , Germán Peces-Barba  4 , Tamara García Barrera  1
Affiliations

Untargeted Metabolomic Study of Lung Cancer Patients after Surgery with Curative Intent

Saida Sanchez-Espirilla et al. J Proteome Res. .

Abstract

Lung cancer (LC) is a leading cause of mortality, claiming more than 1.8 million deaths per year worldwide. Surgery is one of the most effective treatments when the disease is in its early stages. The study of metabolic alterations after surgical intervention with curative intent could be used to assess the response to treatment or the detection of cancer recurrence. In this study, we have evaluated the metabolomic profile of serum samples (n = 110) from preoperative (PRE) and postoperative (POST) LC patients collected at two different time points (1 month, A; 3-6 months, B) with respect to healthy people. An untargeted metabolomic platform based on reversed phase (RP) and hydrophilic interaction chromatography (HILIC), using ultra-high performance liquid chromatography (UHPLC) and mass spectrometry (MS), was applied (MassIVE ID MSV000092213). Twenty-two altered metabolites were annotated by comparing all the different studied groups. DG(14,0/22:1), stearamide, proline, and E,e-carotene-3,3'-dione were found altered in PRE, and their levels returned to those of a baseline control group 3-6 months after surgery. Furthermore, 3-galactosyllactose levels remained altered after intervention in some patients. This study provides unique insights into the metabolic profiles of LC patients after surgery at two different time points by combining complementary analytical methods.

Keywords: hydrophilic interaction; lung cancer; mass spectrometry; metabolomics; serum; surgery; ultra-high performance liquid chromatography.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
3D-PLS-DA scatter plot of (a) MeOH:H2O (8:1 v/v)extracts determined by ESI(+)-RP-UHPLC-QTOF-MS and (b) ESI(−)-RP-UHPLC-QTOF-MS; (c) ACN:MeOH (6:4 v/v) extracts determined by ESI(+)-RP-UHPLC-QTOF-MS; (d) MeOH:H2O (4:1 v/v) extracts determined by ESI(+)-HILIC-UHPLC-QTOF-MS; (e) Venn diagram with the common number of metabolites in the different studied groups. CONTROL: black dots; PRE: green dots; POSTA: blue dots; and POSTB: red dots.
Figure 2
Figure 2
(a) Average abundance heatmap of altered metabolites; (b) most altered subclasses of metabolites when comparing PRE, POSTA, and POSTB groups with the control group.
Figure 3
Figure 3
Abundance of altered metabolites after compassion with the control group: (a) metabolites altered in PRE group and nonaltered after surgery; (b) metabolites altered in PRE and POSTA groups and nonaltered in POSTB; (c) metabolites altered in PRE, POSTA, and POSTB groups with similar trends. *Significant differences (ANOVA-Tukey test) respect to control values. Error bars: standard deviation of the mean (SEM).
See this image and copyright information in PMC

References

    1. Sung H.; Ferlay J.; Siegel R. L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71 (3), 209–249. 10.3322/caac.21660. - DOI - PubMed
    1. Yuan M.; Huang L.-L.; Chen J.-H.; Wu J.; Xu Q. The Emerging Treatment Landscape of Targeted Therapy in Non-Small-Cell Lung Cancer. Signal Transduct. Target Ther. 2019, 4 (1), 61. 10.1038/s41392-019-0099-9. - DOI - PMC - PubMed
    1. Hori S.; Nishiumi S.; Kobayashi K.; Shinohara M.; Hatakeyama Y.; Kotani Y.; Hatano N.; Maniwa Y.; Nishio W.; Bamba T.; Fukusaki E.; Azuma T.; Takenawa T.; Nishimura Y.; Yoshida M. A Metabolomic Approach to Lung Cancer. Lung Cancer 2011, 74 (2), 284–292. 10.1016/j.lungcan.2011.02.008. - DOI - PubMed
    1. Rocha C. M.; Barros A. S.; Goodfellow B. J.; Carreira I. M.; Gomes A.; Sousa V.; Bernardo J.; Carvalho L.; Gil A. M.; Duarte I. F. NMR Metabolomics of Human Lung Tumours Reveals Distinct Metabolic Signatures for Adenocarcinoma and Squamous Cell Carcinoma. Carcinogenesis 2015, 36 (1), 68–75. 10.1093/carcin/bgu226. - DOI - PubMed
    1. Puchades-Carrasco L.; Jantus-Lewintre E.; Pérez-Rambla C.; García-García F.; Lucas R.; Calabuig S.; Blasco A.; Dopazo J.; Camps C.; Pineda-Lucena A. Serum Metabolomic Profiling Facilitates the Non-Invasive Identification of Metabolic Biomarkers Associated with the Onset and Progression of Non-Small Cell Lung Cancer. Oncotarget 2016, 7 (11), 12904–12916. 10.18632/oncotarget.7354. - DOI - PMC - PubMed

Publication types